249 related articles for article (PubMed ID: 12412167)
21. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
[TBL] [Abstract][Full Text] [Related]
22. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
[TBL] [Abstract][Full Text] [Related]
23. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
Morote J; Orsola A; Abascal JM; Planas J; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.
Morote J; Morin JP; Orsola A; Abascal JM; Salvador C; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
Urology; 2007 Mar; 69(3):500-4. PubMed ID: 17382153
[TBL] [Abstract][Full Text] [Related]
25. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
Higano CS
Nat Clin Pract Urol; 2008 Jan; 5(1):24-34. PubMed ID: 18185511
[TBL] [Abstract][Full Text] [Related]
26. Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.
Isahaya E; Hara N; Nishiyama T; Hoshii T; Takizawa I; Takahashi K
Prostate; 2010 Feb; 70(2):155-61. PubMed ID: 19760629
[TBL] [Abstract][Full Text] [Related]
27. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
28. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
Izumi K; Mizokami A; Sugimoto K; Narimoto K; Miwa S; Maeda Y; Kadono Y; Takashima M; Koh E; Namiki M
Urology; 2009 Jun; 73(6):1342-6. PubMed ID: 19371939
[TBL] [Abstract][Full Text] [Related]
29. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
Kiratli BJ; Srinivas S; Perkash I; Terris MK
Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
[TBL] [Abstract][Full Text] [Related]
30. [Effects of body mass index on bone mineral density in men].
Tóth E; Ferenc V; Mészáros S; Csupor E; Horváth C
Orv Hetil; 2005 Jul; 146(28):1489-93. PubMed ID: 16130443
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
Smith MR
Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
[TBL] [Abstract][Full Text] [Related]
32. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
[TBL] [Abstract][Full Text] [Related]
33. Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls.
Delpierre C; Bonnet E; Marion-Latard F; Aquilina C; Obadia M; Marchou B; Massip P; Perret B; Bernard J
J Clin Densitom; 2007; 10(4):376-80. PubMed ID: 17888698
[TBL] [Abstract][Full Text] [Related]
34. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
35. Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study.
Marinovic D; Dorgeret S; Lescoeur B; Alberti C; Noel M; Czernichow P; Sebag G; Vilmer E; Léger J
Pediatrics; 2005 Jul; 116(1):e102-8. PubMed ID: 15995009
[TBL] [Abstract][Full Text] [Related]
36. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.
Yaturu S; DjeDjos S; Alferos G; Deprisco C
Prostate Cancer Prostatic Dis; 2006; 9(1):35-8. PubMed ID: 16276350
[TBL] [Abstract][Full Text] [Related]
37. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
38. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
Morabito N; Gaudio A; Lasco A; Catalano A; Atteritano M; Trifiletti A; Anastasi G; Melloni D; Frisina N
J Bone Miner Res; 2004 Nov; 19(11):1766-70. PubMed ID: 15476575
[TBL] [Abstract][Full Text] [Related]
39. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Smith MR
Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
[TBL] [Abstract][Full Text] [Related]
40. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.
Tanvetyanon T
Cancer; 2005 Jan; 103(2):237-41. PubMed ID: 15597384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]